Narlumosbart - CISMeF

Preferred Label : Narlumosbart;

NCIt synonyms : Anti-RANKL Monoclonal Antibody JMT103;

NCIt definition : A recombinant, human, immunoglobulin G4 (IgG4) monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL), with potential antiosteoclast and bone-sparing activities. Upon administration, narlumosbart specifically binds to RANKL and blocks the interaction of RANKL with RANK, a receptor located on osteoclast cell surfaces. This may inhibit osteoclast activity, decrease bone resorption, increase bone mineral density, and may protect bones from tumor metastasis. This may abrogate hypercalcemia of malignancy and may correct serum calcium levels. RANKL, a protein expressed by osteoblastic cells, plays an important role in osteoclastic differentiation and activation. Both RANKL and RANK are overexpressed in certain bone tumors, and the RANK/RANKL-mediated signaling pathway plays an important role in certain bone tumors.;

UNII : J38KT46AH8;

CAS number : 2646587-68-8;

Molecule name : JMT 103; JMT-103;

NCI Metathesaurus CUI : CL1798893;

Details

Origin ID

C190458;

UMLS CUI

C5783725;

Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Tumor Necrosis Factor Ligand Superfamily Member 11 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients